|本期目录/Table of Contents|

[1]李兆雪,杨吉龙,朱泽.新型冠状病毒感染对恶性周围神经鞘瘤复发的观察性研究[J].天津医科大学学报,2025,31(03):268-273,387.[doi:10.20135/j.issn.1006-8147.2025.03.0268]
　LI Zhaoxue,YANG Jilong,ZHU Ze.An observational study on the effect of SARS-CoV-2 infection on the recurrence of malignant peripheral nerve sheath tumors[J].Journal of Tianjin Medical University,2025,31(03):268-273,387.[doi:10.20135/j.issn.1006-8147.2025.03.0268]
点击复制

新型冠状病毒感染对恶性周围神经鞘瘤复发的观察性研究(PDF)

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
31卷
期数:
2025年03期
页码:
268-273,387
栏目:
临床医学
出版日期:
2025-05-20

文章信息/Info

Title:
An observational study on the effect of SARS-CoV-2 infection on the recurrence of malignant peripheral nerve sheath tumors
文章编号:
1006-8147(2025)03-0268-07
作者:
李兆雪1; 2; 杨吉龙3; 朱泽1
（1.天津医科大学基础医学院病原生物学系，天津 300070；2.天津市津南医院检验科，天津 300350；3.天津医科大学肿瘤医院骨与软组织肿瘤科，天津 300060）
Author(s):
LI Zhaoxue1; 2; YANG Jilong3; ZHU Ze1
（1.Department of Pathogen Biology，School of Basic Medical Sciences，Tianjin Medical University，Tianjin 300070，China；2. Clinical Laboratory，Tianjin Jinnan Hospital，Tianjin 300350，China；3. Department of Bone and Soft Tissue Oncology，Tianjin Medical University Cancer Institute & Hospital，Tianjin 300060，China）
关键词:
恶性周围神经鞘瘤; 新型冠状病毒感染; 复发; 生存曲线
Keywords:
malignant peripheral nerve sheath tumor; SARS-CoV-2 infection; recurrence; survival curve
分类号:
R739.43
DOI:
10.20135/j.issn.1006-8147.2025.03.0268
文献标志码:
A
摘要:
目的：探讨新型冠状病毒（SARS-CoV-2）感染对恶性周围神经鞘瘤（MPNST）患者的影响，为MPNST患者的个体化治疗提供科学依据。方法：收集并分析天津医科大学肿瘤医院2018年1月至2023年12月经病理确诊为MPNST的患者数据，共纳入 48 例，根据是否感染SARS-CoV-2分为感染组（19 例）与对照组（29 例），通过电话的方式对两组患者进行随访。卡方检验及Fisher确切检验用于患者生存、复发、转移等指标的对比，Kaplan-Meier法用于计算生存曲线，Log-rank检验比较不同组间生存曲线的差异，Cox回归分析检验SARS-CoV-2感染是否为MPNST患者疾病进展的独立危险因素。结果：本研究对 48 例MPNST患者进行了分析，发现肿瘤原发部位以四肢最常见，占比43.7%。组织学分级以高级别肿瘤为主，占比79.2%。肿瘤平均最大直径约为 6.3 cm。病理学上，MPNST主要表现为恶性梭形细胞肉瘤，且S-100阳性表达率77.1%。在复发与转移方面，感染组复发率（57.9%）显著高于对照组（24.1%），差异具有统计学意义（χ2=5.581，P=0.018）。然而，在总死亡、总疾病进展、单纯转移及特定部位转移等方面，两组间未观察到差异具有统计学意义（均P＞0.05）。单因素分析结果显示，SARS-CoV-2感染与MPNST复发有显著相关性（χ2=5.581，P=0.018），然而，年龄、肿瘤大小、S-100表达状态、组织学分级等因素与MPNST复发无关（均P＞0.05）。感染组从SARS-CoV-2检测阳性后发生疾病进展的中位时间较对照组短（11个月 vs. 15个月，P=0.047）。但多因素Cox回归分析显示，SARS-CoV-2感染并非MPNST患者疾病进展的独立危险因素（P=0.186）。结论：SARS-CoV-2感染可能增加MPNST患者的复发风险，加速疾病进展，但对总生存期没有影响。。
Abstract:
Objective：To investigate the impact of SARS-CoV-2 infection on patients with malignant peripheral nerve sheath tumor （MPNST），aiming to provide a scientific basis for individualized treatment of patients with MPNST. Methods：Data from patients with pathologically confirmed MPNST at Tianjin Medical University Cancer Institute & Hospital between January，2018 and December，2023 were collected and analyzed，with a total of 48 patients included. The patients were divided into infected group （19 patients） and control group （29 patients） based on their COVID-19 infection status. Follow-up on the conditions of patients in both groups was conducted via telephone. Chi-square test and Fisher′s exact test were used to compare survival，recurrence，metastasis，and other indicators. Kaplan-Meier method was employed to calculate survival curves，and Log-rank test was used to compare differences in survival curves between different groups. Cox regression analysis was conducted to test whether SARS-CoV-2 infection was an independent risk factor for disease progression in patients with MPNST. Results：This study analyzed 48 MPNST patients and found that the primary tumor site was most commonly located in the extremities，accounting for 43.7% of cases. The histological grading was predominantly high-grade tumors，accounting for 79.2% of the cases. The average maximum diameter of the tumors was approximately 6.3 cm. Pathologically，MPNST mainly manifests as a malignant spindle cell sarcoma，with an S-100 positive expression rate of 77.1%. In terms of recurrence and metastasis，the recurrence rate in the infected group （57.9%） was significantly higher than that in the control group （24.1%），with a statistically significant difference （χ2=5.581，P=0.018）. However，no statistically significant differences were observed between the two groups in terms of overall mortality，overall disease progression，pure metastasis，and metastasis to specific sites （all P>0.05）. The results of univariate analysis showed a significant correlation between SARS-CoV-2 infection and MPNST recurrence （χ2=5.581，P=0.018）. However，factors such as age，tumor size，S-100 expression status，and histological grade were not significantly associated with MPNST recurrence （all P>0.05）. The median time for disease progression after a positive SARS-CoV-2 test in the infected group was shorter than that in the control group （11 months vs. 15 months，P=0.047）. Yet，multivariate Cox regression analysis showed that SARS-CoV-2 infection was not an independent risk factor for disease progression in patients with MPNST （P=0.186）. Conclusion：SARS-CoV-2 infection may increase the risk of recurrence and accelerate disease progression in patients with MPNST，but it has no impact on overall survival.

参考文献/References:

[1] ROTHAN H A，BYRAREDDY S N. The epidemiology and pathogenesis of coronavirus disease （COVID-19） outbreak[J]. J Autoimmun，2020，109：102433.
[2] WANG H D，PAULSON K R， PEASE S A，et al. Estimating excess mortality due to the COVID-19 pandemic：a systematic analysis of COVID-19-related mortality，2020-21[J]. Lancet，2022，399（10334）：1513-1536.
[3] XIONG N，SUN Q. How does SARS-CoV-2 infection impact on immunity，procession and treatment of pan cancers[J]. J Med Virol，2023，95（2）：e28487.
[4] OGAREK N，OBOZA P，OLSZANECKA-GLINIANOWICZ M，et al. SARS-CoV-2 infection as a potential risk factor for the development of cancer[J]. Front Mol Biosci，2023，10：1260776.
[5] SARKAR S R，SINGHAVI H R，DAS A，et al. Effects of viral infections like COVID-19 on head and neck cancers：the role of neutrophil-lymphocyte counts and ratios[J]. Cureus，2024，16（6）：e61733.
[6] GREGORY T A，KNIGHT S R，AAROE A E，et al. Accelerated tumor progression after COVID-19 infection in patients with glioblastoma：a retrospective case-control study[J]. Neurooncol Pract，2024， 11（4）：475-483.
[7] PENG Y L，WANG Z Y，ZHONG R W，et al. Association of COVID-19 and lung cancer：short-term and long-term interactions[J].Cancers （Basel），2024 ，16（2）：304.
[8] CHEN J，DAI L，BARRETT L，et al. SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus[J]. Commun Biol，2021，4（1）：682.
[9] LAMBAREY H，BLUMENTHAL M J，CHETRAM A，et al. Reactivation of Kaposi′s sarcoma-associated herpesvirus （KSHV） by SARS-CoV-2 in non-hospitalised HIV-infected patients[J]. EBio- Medicine，2024，100：104986.
[10] LI J，BAI H，QIAO H，et al. Causal effects of COVID-19 on cancer risk：a Mendelian randomization study[J]. J Med Virol，2023，95（4）：e28722.
[11] WANG H，FANG N，MOZUMDER P，et al. Exploring the protective association between COVID-19 infection and laryngeal cancer：insights from a Mendelian randomization study[J]. Front Immunol，2024，15：1380982.
[12] RAGONE C，MAURIELLO A，CAVALLUZZO B，et al. Molecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization[J]. Front Immunol，2024，15：1398002.
[13] TROJANI M，CONTESSO G，COINDRE J M，et al. Soft-tissue sarcomas of adults；study of pathological prognostic variables and definition of a histopathological grading system[J]. Int J Cancer，1984， 33（1）：37-42.
[14] 中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案（试行第十版）[J]. 中国合理用药探索，2023，20（1）：1-11.
[15] TAY M Z，POH C M，R?魪NIA L，et al. The trinity of COVID-19：immunity，inflammation and intervention[J]. Nat Rev Immunol，2020， 20（6）：363-374.
[16] JIANG R D，LIU M Q，CHEN Y，et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2[J]. Cell，2020，182（1）：50-58.
[17] HUANG C，WANG Y，LI X，et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan，China[J]. Lancet，2020，395（10223）：497-506.
[18] ZHOU R，TO K K，WONG Y C，et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses[J]. Immunity，2020，53（4）：864-877.
[19] QIN C，ZHOU L，HU Z，et al. Dysregulation of immune response in patients with Coronavirus 2019 （COVID-19） in Wuhan，China[J]. Clin Infect Dis，2020，71（15）：762-768.
[20] DU PLESSIS M，FOURIE C，RIEDEMANN J，et al. Cancer and Covid-19：collectively catastrophic[J]. Cytokine Growth Factor Rev，2022，63：78-89.
[21] CHAKRABORTY C，SHARMA A R，BHATTACHARYA M，et al. A detailed overview of immune escape，antibody escape，partial vaccine escape of SARS-CoV-2 and their emerging variants with escape mutations[J]. Front Immunol，2022，13：801522.
[22] SUN D，XIE X P，ZHANG X，et al. Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression[J].Cell Stem Cell，2021，28（8）：1397-1410.
[23] GUTMANN D H，FERNER R E，LISTERNICK R H，et al. Neurofibromatosis type 1[J]. Nat Rev Dis Primers，2017，3：17004.
[24] MIETTINEN M M，ANTONESCU C R，FLETCHER CDM，et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview[J]. Hum Pa-thol，2017，67：1-10.
[25] SOMATILAKA B N，SADEK A，MCKAY R M，et al. Malignant peripheral nerve sheath tumor：models，biology，and translation[J]. Oncogene，2022，41（17）：2405-2421.
[26] SUPPIAH S，MANSOURI S，MAMATJAN Y，et al. Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities[J]. Nat Commun，2023，14（1）：2696.
[27] KHAN S，SHAFIEI M S，LONGORIA C，et al. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway[J]. Elife，2021，10：e68563.
[28] RAPTI V，TSAGANOS T，VATHIOTIS I A，et al. New insights into SARS-CoV-2 and cancer cross-talk：does a novel oncogenesis driver emerge[J]. Vaccines （Basel），2022，10（10）：1607.
[29] MATTICK J S，AMARAL P P，CARNINCI P，et al. Long non-coding RNAs：definitions，functions，challenges and recommendations[J]. Nat Rev Mol Cell Biol，2023，24（6）：430-447.
[30] BEHURA A，NAIK L，PATEL S，et al. Involvement of epigenetics in affecting host immunity during SARS-CoV-2 infection[J]. Biochim Biophys Acta Mol Basis Dis，2023，1869（3）：166634.
[31] MA-LAUER Y，CARBAJO-LOZOYA J，HEIN M Y，et al. P53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1[J]. Proc Natl Acad Sci U S A，2016 ，113（35）：E5192-201.
[32] 刘娟，曹雪涛. 2023年国内外免疫学研究重要进展[J]. 中国免疫学杂志，2024，40（1）：1-10.

相似文献/References:

[1]宋紫暄,李光明,张 静,等.H3K27三甲基化蛋白可作为MPNST的重要诊断标记物[J].天津医科大学学报,2018,24(04):353.
　SONG Zi-xuan,LI Guang-ming,ZHANG Jing,et al.H3K27me3 is a highly sensitive diagnostic marker for MPNST[J].Journal of Tianjin Medical University,2018,24(03):353.
[2]孙硕遥,高雅,朱香熹,等.吉非替尼通过促进H3K27甲基化水平抑制恶性周围神经鞘瘤细胞的增殖[J].天津医科大学学报,2021,27(03):211.
　SUN Shuo-yao,GAO Ya,ZHU Xiang-xi,et al.Gefitinib inhibits the proliferation of malignant peripheral nerve sheath tumor cells by promoting H3K27 methylation levels[J].Journal of Tianjin Medical University,2021,27(03):211.
[3]高雅,赵洋,朱香熹,等.司美替尼对恶性周围神经鞘瘤细胞增殖和凋亡的影响[J].天津医科大学学报,2022,28(01):40.
　GAO Ya,ZHAO Yang,ZHU Xiang-xi,et al.The effect of selumetinib on cell proliferation and apoptosis of malignant peripheral nerve sheath tumor[J].Journal of Tianjin Medical University,2022,28(03):40.
[4]赵洋,孙亚敏,朱香熹,等.LATS2对恶性周围神经鞘瘤细胞的调控作用及分子机制探讨[J].天津医科大学学报,2023,29(02):120.
　ZHAO Yang,SUN Ya-min,ZHU Xiang-xi,et al.Regulatory effect and molecular mechanism of LATS2 on malignant peripheral nerve sheath tumor cells[J].Journal of Tianjin Medical University,2023,29(03):120.
[5]孙亚敏,朱香熹,陈毓锴,等.萝卜硫素预防Ⅰ型神经纤维瘤病恶性进展的作用机制研究[J].天津医科大学学报,2024,30(02):105.[doi:10.20135/j.issn.1006-8147.2024.02.0105]
　SUN Yamin,ZHU Xiangxi,CHEN Yukai,et al.The effect and mechanism of sulforaphane in preventing malignant progression of neurofibromatosis type Ⅰ[J].Journal of Tianjin Medical University,2024,30(03):105.[doi:10.20135/j.issn.1006-8147.2024.02.0105]

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金（81672650）
作者简介: 李兆雪（1994-），女，硕士在读，研究方向：病原生物学；
通信作者：朱泽，E-mail：zhuze@tmu.edu.cn。
更新日期/Last Update: 2025-06-01